Valuation
- Market cap
- 8,994,463,000
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- 0.00
- Forward PE
- 22.65
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 10,024
- Avg volume
- 60,018
- Day's range
- $7.90 – $7.93
- Shares out
- 1,166,597,000
- Stochastic %K
- 97%
- Beta
- 0.19
- Analysts
- Sell
- Price target
- —
Company profile
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compo...
Show more
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 81 3 3817 3700
- Website
- https://www.eisai.co.jp
- Address
- 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
Latest news
No headlines yet.
